

Information about proposed Board of Directors Annual General Meeting 2026

Proposal for re-election of the current members of the Board of Directors:

Christophe Bourdon

Born 1970. Master of Business Administration from International Institute for Management (IMD) Business School, Switzerland, and a BA from ISG Business School, France. Board member since 2023.

Other appointments: CEO of Leo Pharma A/S.

Previous appointments: CEO of Orphazyme A/S, Senior Vice President, General Manager, U.S. Oncology Business and member of the Operating Team at Amgen Inc., Senior Vice President of Europe, Middle East, Africa and Canada at Alexion, as well as other key roles within the international pharmaceutical industry.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Iris Loew-Friedrich

Born 1960. MD, PhD in internal medicine from Goethe University Frankfurt, Germany. Board member since 2025.

Other appointments: Chair of the Board of Evotec SE and of Celosia Therapeutics Pty Ltd. Board member of Fresenius SE & Co. KGaA and Financière de Tubize. Member of the advisory boards of Fondazione Telethon, Pierre Fabre S.A. and Helmholtz Health.

Previous appointments: Executive Vice President, Chief Medical Officer and Head of Development at UCB S.A./Schwarz Pharma AG, Vice President, Head of Global Development at BASF Pharma and various positions in clinical development at Aventis/Hoechst Marion Roussel/Hoechst AG (changed names due to mergers).

Shares: 1,900

Independent in relation to the company and its management and in relation to the company's principal shareholders.

David Meek

Born 1963. Bachelor of Arts (Management) from the University of Cincinnati, USA. Board member and Chair since 2024.

Other appointments: Board member of Cullinan Therapeutics, uniQure (Chair) and the University of Southern California School of Pharmacy and Pharmaceutical Sciences. CEO of Genetix Biotherapeutics Inc.

Previous appointments: Chief Executive Officer and Board Director of Mirati Therapeutics Inc, FerGene Inc and Ipsen SA. Senior executive positions at Baxalta Inc, Endocyte Inc, Novartis Pharmaceuticals and Johnson & Johnson

Shares: 3,843

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Staffan Schüberg

Born 1969. Bachelor of Arts (Hons) Business Administration from the London Guildhall University, United Kingdom. Board member since 2020.

Other appointments: CEO of the ESTEVE Group. Board member of Dizlin Pharmaceuticals AB and Corporación Químico Farmacéutico Esteve S.A.

Previous appointments: More than 20 years of experience from Board and executive management roles, including several senior positions within Lundbeck A/S, such as Regional Vice President for Southern and Western Europe, President and Chairman of the U.S. operations and Global Chief Commercial Officer on Group level.

Shares: 7,142

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Filippa Stenberg

Born 1985. Master of Science in economics from Stockholm School of Economics, Sweden. Board member since 2021.

Other appointments: Managing Director at Patricia Industries, part of Investor AB. Board member of Affibody Medical AB. Deputy Board member of Mölnlycke Health Care.

Previous appointments: Managing Director Listed Companies, Investor AB. Chief Strategy Officer at Atlas Antibodies. Analyst at Swedbank LC&I.

Shares: 2,971

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Proposal for election of new members of the Board of Directors:

Mikael Dolsten

Born 1958. MD, PhD in tumor immunology and Visiting Professorship from University of Lund, Sweden.

Other appointments: Board member of Agilent Technologies, Rocket Pharmaceuticals, Apellis Pharmaceuticals, ChAI discovery, BenchSci, ImmuneAi, Orbis Medicines, Quarry Thera, Enveda Bio and Fair Journey Bio. Senior advisor to Google Ventures (GV), Blackstone, Bain & Co and Scripps Cailbr research institute.

Previous appointments: 16 years tenure as Chief Scientific Officer and President of Research & Development-Medical at Pfizer and various leading roles within Wyeth Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Pharmacia and Vimian Group AB.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Åsa Riisberg

Born 1974. M.Sc. in Business Administration from Stockholm School of Economics, Sweden.

Other appointments: Chair of the Board of Atlas Antibodies AB. Board member of Patricia Industries, Bonnier Group, Netcompany, Stena Adactum, Qarlbo and Internetmedicin. Lead Director at MFIN at the Stockholm School of Economics.

Previous appointments: Former partner at EQT, where she spent 20 years as deal partner, Global Head of EQT's Healthcare Sector, Head of Shareholder Relations and part of EQT's Extended Executive Committee. Prior to EQT, she was with Texas Pacific Group and Morgan Stanley in London.

Shares: 31,046

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.